Chikako Kaminaka

Chikako Kaminaka

Auto-generated profile, based on publicly available information

Chikako Kaminaka

Department of Dermatology Wakayama Medical University Wakayama Japan

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2009 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
CKChikako Kaminaka
Chikako Kaminaka
YYYuki Yamamoto
Yuki Yamamoto
NYNozomi Yonei
Nozomi Yonei
AKAkiko Kishioka
Akiko Kishioka
TKToshikazu Kondo
Toshikazu Kondo
FFFukumi Furukawa
Fukumi Furukawa

9 April 2015 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
CKChikako Kaminaka
Chikako Kaminaka
MUMikiko Uede
Mikiko Uede
HMHiroshi Matsunaka
Hiroshi Matsunaka
FFFukumi Furukawa
Fukumi Furukawa
YYYuki Yamamoto
Yuki Yamamoto

1 January 2012 in ACTA HISTOCHEMICA ET CYTOCHEMICA
Verified
Journal Article
Open access
STSeiko Toyozawa
Seiko Toyozawa
CKChikako Kaminaka
Chikako Kaminaka
FFFukumi Furukawa
Fukumi Furukawa
YNYasushi Nakamura
Yasushi Nakamura
HMHiroshi Matsunaka
Hiroshi Matsunaka
YYYuki Yamamoto
Yuki Yamamoto
The CXCR4/CXCL12 pathway has recently been reported to be involved in stimulating the metastasis of many different neoplasms, in which CXCR4 activates various phenomena such as chemotaxis, invasion, angiogenesis and proliferation. The purpose of this study was to analyze a possible association between the expression of chemokine receptors CXCR4, CCR6 and CCR7 with the clinicopathological features of cutaneous malignant melanoma, and to assess the usefulness of these chemokine receptors for diagnosis and prognosis. In our study, a percentage of immunoexpression of both CXCR4 and its ligands CXCL12 was associated with high clinical risk. In contrast, the patients with a low immunoexpression of CXCR4 and CXCL12 had low clinical risk. CCR6 and CCR7 immunoexpressions were also correlated with some clinical parameters, but seemed no more useful than CXCR4. These data suggest that the assessment of CXCR4 immunoexpression is a novel tool for predicting tumor aggressiveness in malignant melanomas, and in particular, a high immunoexpression percentage of CXCR4 and CXCL12 might be a sign of a poor prognosis.

27 February 2019 in Lasers in Surgery and Medicine
Verified
Journal Article
Closed access
PDF file
CKChikako Kaminaka
Chikako Kaminaka
NMNaoya Mikita
Naoya Mikita
YIYutaka Inaba
Yutaka Inaba
KKKayo Kunimoto
Kayo Kunimoto
HOHisako Okuhira
Hisako Okuhira
YYYuki Yamamoto
Yuki Yamamoto

24 February 2022 in Children
Verified
Journal Article
Open access
PDF file
YIYutaka Inaba
Yutaka Inaba
Nobuo KanazawaNobuo Kanazawa
Nobuo Kanazawa
KMKyoko Muraoka
Kyoko Muraoka
AYAzusa Yariyama
Azusa Yariyama
AKAmi Kawaguchi
Ami Kawaguchi
MJMasatoshi Jinnin
Masatoshi Jinnin
The patient was a 26-year-old male. He had red and scaling skin of the entire body since birth, as well as an elevated level of serum IgE. Genetic testing revealed a mutation in the SPINK5 gene, which had confirmed the diagnosis with Netherton syndrome. He has had significant pruritis since birth, and subsequently had symptoms of sleeping disorders and concentration difficulty throughout the day. Since treatment with various antihistamines were not effective, we administered dupilumab and found that it was effective in immediate elimination of pruritus and gradual reduction of the rash. Dupilumab has been administered for one year without any adverse events or recurrence of symptoms. Although studies have previously described cases who used dupilumab for Netherton syndrome, reported effects have been limited or transient. Additional studies are needed to confirm the effect of dupilumab for Netherton syndrome, which currently lack any effective treatment strategies.

6 May 2014 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
CKChikako Kaminaka
Chikako Kaminaka
MUMikiko Uede
Mikiko Uede
YNYasushi Nakamura
Yasushi Nakamura
FFFukumi Furukawa
Fukumi Furukawa
YYYuki Yamamoto
Yuki Yamamoto